These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35340486)

  • 1. Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines.
    Gil L; Alves FR; Silva D; Fernandes I; Fontes-Sousa M; Alves M; Papoila A; Da Luz R
    Cureus; 2022 Feb; 14(2):e22224. PubMed ID: 35340486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.
    Tucker MD; Brown LC; Chen YW; Kao C; Hirshman N; Kinsey EN; Ancell KK; Beckermann KE; Davis NB; McAlister R; Schaffer K; Armstrong AJ; Harrison MR; George DJ; Rathmell WK; Rini BI; Zhang T
    Biomark Res; 2021 Nov; 9(1):80. PubMed ID: 34732251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab.
    Beulque Y; Kinget L; Roussel E; Mobaraki S; Laenen A; Debruyne PR; Van Herck Y; Baldewijns M; Wozniak A; Garg AD; Zucman-Rossi J; Couchy G; Albersen M; De Wever L; Haaker L; Beuselinck B
    Acta Oncol; 2024 Aug; 63():658-668. PubMed ID: 39129249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma.
    Chen YW; Tucker MD; Brown LC; Yasin HA; Ancell KK; Armstrong AJ; Beckermann KE; Davis NB; Harrison MR; Kaiser EG; McAlister RK; Schaffer KR; Wallace DE; George DJ; Rathmell WK; Rini BI; Zhang T
    Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
    Suzuki S; Abe T; Endo T; Kaya H; Kitabayashi T; Kawasaki Y; Yamada T
    Cancer Manag Res; 2022; 14():3293-3302. PubMed ID: 36452436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Zhuang TZ; Ravindranathan D; Liu Y; Martini DJ; Brown JT; Nazha B; Russler G; Yantorni LB; Caulfield S; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2023 Mar; 28(3):239-245. PubMed ID: 36427017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
    Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
    Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab.
    Catalano M; Rebuzzi SE; Maruzzo M; De Giorgi U; Buti S; Galli L; Fornarini G; Zucali PA; Procopio G; Chiellino S; Milella M; Catalano F; Pipitone S; Ricotta R; Sorarù M; Mollica V; Tudini M; Fratino L; Prati V; Caffo O; Atzori F; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Di Napoli M; Malgeri A; Naglieri E; Signori A; Banna GL; Rescigno P; Antonuzzo L; Roviello G
    JAMA Netw Open; 2023 Nov; 6(11):e2345185. PubMed ID: 38010650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy.
    Pozorski V; Park Y; Mohamoud Y; Tesfamichael D; Emamekhoo H; Birbrair A; Albertini MR; Ma VT
    Pigment Cell Melanoma Res; 2023 Nov; 36(6):501-511. PubMed ID: 37903733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma.
    Drljevic-Nielsen A; Donskov F; Mains JR; Andersen MB; Thorup K; Thygesen J; Rasmussen F
    AJR Am J Roentgenol; 2022 May; 218(5):867-876. PubMed ID: 34910540
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: which is better?
    Halit Aktepe O; Sinem Ardic F; Yuce D; Can Guven D; Guner G; Cagri Yildirim H; Kilickap S; Turker A; Kertmen N; Akin S; Aksoy S; Dizdar O; Yalcin S; Erman M
    J BUON; 2021; 26(5):2067-2073. PubMed ID: 34761618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients.
    Kankkunen E; Penttilä P; Peltola K; Bono P
    Acta Oncol; 2022 Oct; 61(10):1240-1247. PubMed ID: 35905053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.
    Nukaya T; Takahara K; Yoshizawa A; Saruta M; Yano Y; Ohno T; Uchimoto T; Fukuokaya W; Adachi T; Yamazaki S; Tokushige S; Nishimura K; Tsujino T; Nakamori K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Hirasawa Y; Hashimoto T; Komura K; Inamoto T; Miki J; Kimura T; Ohno Y; Azuma H; Shiroki R
    Clin Genitourin Cancer; 2024 Feb; 22(1):76-83. PubMed ID: 37880020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade.
    Olsen TA; Martini DJ; Goyal S; Liu Y; Evans ST; Magod B; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Harris WB; Kucuk O; Carthon BC; Master VA; Nazha B; Bilen MA
    Front Oncol; 2021; 11():701345. PubMed ID: 34222024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study.
    Herrmann T; Ginzac A; Molnar I; Bailly S; Durando X; Mahammedi H
    Cancer Med; 2021 Oct; 10(19):6705-6713. PubMed ID: 34405573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
    Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
    J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers.
    Verhaart SL; Abu-Ghanem Y; Mulder SF; Oosting S; Van Der Veldt A; Osanto S; Aarts MJB; Houtsma D; Peters FPJ; Groenewegen G; Van Herpen CML; Pronk LM; Tascilar M; Hamberg P; Los M; Vreugdenhil G; Polee M; Ten Tije AJ; Haanen JBAG; Bex A; van den Eertwegh AJ
    Clin Genitourin Cancer; 2021 Jun; 19(3):274.e1-274.e16. PubMed ID: 33317946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.